In short, we concluded that two polymorphisms (rs334348, rs10512263) in <i>TGFBR1</i> were associated with risk of gastric cancer, and that <i>TLR4</i> rs1927911 and <i>TGFBR1</i> rs10512263 were associated with clinical outcomes of gastric cancer patients.
In short, we concluded that two polymorphisms (rs334348, rs10512263) in <i>TGFBR1</i> were associated with risk of gastric cancer, and that <i>TLR4</i> rs1927911 and <i>TGFBR1</i> rs10512263 were associated with clinical outcomes of gastric cancer patients.
After combining the two stages, we found that these two SNPs were associated with a significantly increased risk of gastr</span>ic cancer in dominant models [adjusted odds ratio (OR) = 1.36, 95% confidence interval (CI): 1.14-1.63 for rs6478974 AT/AA vs. TT; adjusted OR = 1.26, 95% CI: 1.05-1.50 for rs10512263 CT/CC vs. TT] or additive model (adjusted OR = 1.23, 95% CI: 1.08-1.40 for rs6478974).
After combining the two stages, we found that these two SNPs were associated with a significantly increased risk of gastr</span>ic cancer in dominant models [adjusted odds ratio (OR) = 1.36, 95% confidence interval (CI): 1.14-1.63 for rs6478974 AT/AA vs. TT; adjusted OR = 1.26, 95% CI: 1.05-1.50 for rs10512263 CT/CC vs. TT] or additive model (adjusted OR = 1.23, 95% CI: 1.08-1.40 for rs6478974).
Classification and regression tree (CART) demonstrated that women carrying both the genotypes of TGFBR1 rs6478974 TT and rs10512263 TC/CC had the highest risk of EC (aOR = 7.86, 95% CI = 3.42-18.07, P<0.0001).
Classification and regression tree (CART) demonstrated that women carrying both the genotypes of TGFBR1 rs6478974 TT and rs10512263 TC/CC had the highest risk of EC (aOR = 7.86, 95% CI = 3.42-18.07, P<0.0001).